Cardio Catch-Up: Medtronic, Recor, Pulnovo Report Progress On Denervation To Treat Hypertension
The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.
You may also be interested in...
News We're Watching: Renal Denervation Trial Highlights, TAP Pilot Update, Cardiohelp Safety Alert
Two new studies support ReCor’s Radiance Ultrasound Renal Denervation System, and renal denervation also won the backing of European medical societies. Additionally, the FDA issued an update on the Total Product Life Cycle Advisory Program (TAP) “soft” pilot, and a disposable component of the Getinge/Maquet Cardiohelp system was flagged for possible sterility issues.
Cardiovascular Catch-Up: Cardiac Implants Puts Ring Around Tricuspid Annulus; Boston Scientific’s Acurate neo2 TAVR Progresses; Medtronic Promotes New Stroke Plan
This edition of Medtech Insight’s regular round-up of some recent cardiovascular technology news and conversations you may have missed, including updates from Cardiac Implants, Boston Scientific, HeartBeam and Medtronic.
Medtronic Completes PMA Application For Symplicity Spyral Hypertension Device
The six-month results from SPYRAL HTN ON MED trial of Medtronic’s Symplicity Spyral renal denervation system did not meet its primary endpoint, but the company and analysts expect the FDA will still approve Symplicity Spyral as the first renal denervation system available in the US to treat uncontrolled hypertension.